• 1
    Murphy WM, Busch C, Algaba F. Intraurothelial lesions of urinary bladder: morphologic considerations. Scand J Urol Nephrol. 2000; 205 (Suppl): 6781.
  • 2
    Mostofi FK, Davis CJ, Sesterhenn I. Histological typing of urinary bladder tumours. World Health Organization international histological classification of tumours. Berlin: Springer, 1999.
  • 3
    Soloway MS, Murphy W, Rao MK Cox C. Serial multiple-site biopsies in patients with bladder cancer. J Urol. 1978; 120: 5759.
  • 4
    Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol. 1990; 21: 886896.
  • 5
    Bastacky S, Ibrahim S, Wlczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer. 1999; 87: 118128.
  • 6
    Kriegmair M, Knüchel R, Stepp H, Hofstaedter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996; 155: 105110.
  • 7
    Jichlinski P, Forrer M, Mizeret J, et al. Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med. 1997; 20: 402408.
  • 8
    Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid—results of 1012 fluorescence endoscopies. Urology. 2001; 57: 690694.
  • 9
    Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. World Health Organization international classification of tumours, no. 10. Geneva: World Health Organization, 1973.
  • 10
    Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol. 1990; 21: 886896.
  • 11
    Cheng L, Chevilee JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol. 1999; 23: 443447.
  • 12
    Witjes JA, Kiemeney LALM, Verbeeek ALM, Heijbroeck RP, DeBruyne FMJ. Random bladder biopsies and the risk of recurrent superficial bladder cancer—a prospective study in 1026 patients. World J Urol. 1992; 10: 231234.
  • 13
    Cohen SM, Shirai T, Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol. 2000; 205 (Suppl): 105115.
  • 14
    Hellsten S, Berg T, Wehlin L. Unrecognized renal cell carcinoma: clinical and diagnostic aspects. Scand J Urol Nephrol. 1981; 15: 269272.
  • 15
    Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol. 1954; 68: 603.
  • 16
    Althausen AF, Prout GR, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 1976; 116: 575580.
  • 17
    Kiemeney LA, Witjes JA, Heijbroek RP, Debruyne FM, Verbeek AL. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur J Cancer. 1994; 30A: 16211615.
  • 18
    Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer. 2000; 88: 625631.
  • 19
    Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 in addition to p53 alterations in multifocal dysplasia carcinoma in situ of human urinary bladder. Cancer Res. 2002; 62: 808818.
  • 20
    Wijkström H, Cohen SM, Gardiner RA, et al. Prevention and treatment of urothelial premalignant and malignant lesions. Scand J Urol Nephrol. 2000; 205 (Suppl): 116135.
  • 21
    König F, McGovern FJ, Larne R, Enquist H, Schomacker KT, Deutsch TF. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced 5-aminolaevulinic acid. BJU Int. 1999; 83: 129135.
    Direct Link:
  • 22
    Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. Clinical results of the transurethral resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol. 1999; 13: 117121.
  • 23
    Kratzer W, Rothenberger KH. Erfahrungen in der 5-Aminolävulinsäurecystoskopie mit histologischer Absicherung (01/1996–04/1999). In: RothenbergerKH, editor. Licht ins Dunkel. Landshut: Kneidl und Pfaffinger, 1999: 4344.
  • 24
    Kurth KH. Diagnosis and treatment of superficial transitional cell carcinoma of the bladder: facts and perspectives. Eur Urol. 1997; 31 (Suppl 1): 1019.
  • 25
    Badalament RA, Fair WR, Whitmore WF, Melamed MR. The relative value of cytometry and cytology in the management of bladder cancer: the Memorial Sloan-Kettering Cancer Center experience. Semin Urol. 1988; 6: 2230.